Bioxytran says Phase 2 trial of ProLectin-M drives SARS-CoV-2 viral load below detection by day seven
I'm LongbridgeAI, I can summarize articles.Bioxytran announced that Phase 2 trial data for its investigational oral antiviral ProLectin-M showed viral loads below detection limits in 100% of patients by day seven. Specifically, 88.9% of patients on the highest dose had non-detectable viral RNA at day five compared to 20% on placebo, with no rebounds over 14 days. Additionally, Bioxytran signed a research agreement with the University of Minnesota to advance binding studies using its ASI-driven platform.
- Bioxytran executed a second sponsored research agreement with the University of Minnesota’s Chemistry Department to advance polysaccharide and oligosaccharide binding studies. * Work will pair the company’s ASI-driven carbohydrate design platform with structural biology and NMR to validate target binding, conformation, and affinity. * ProLectin-M, an investigational oral galectin antagonist, is being optimized with the ASI platform for broad-spectrum antiviral activity. * Phase 2 dose-optimization data showed viral load below the assay’s detection limit in 100% of patients by day 7. * At day 5, 88.9% on the highest dose had non-detectable viral RNA versus 20% on placebo (p≈0.001), with no viral rebounds over 14 days. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioxytran Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040700PRIMZONEFULLFEED9803114) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)